

# Dae-Seog Heo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/105929/publications.pdf>

Version: 2024-02-01

325  
papers

15,512  
citations

17440

63  
h-index

24982

109  
g-index

330  
all docs

330  
docs citations

330  
times ranked

19741  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea. <i>Cancer Research and Treatment</i> , 2022, 54, 20-29.	3.0	5
2	Primary Prophylaxis for <i>Pneumocystis jirovecii</i> Pneumonia in Patients Receiving Rituximab. <i>Chest</i> , 2022, 161, 1201-1210.	0.8	23
3	Hospice-Palliative Medicine as a Model of Value-based Healthcare. <i>Journal of Korean Medical Science</i> , 2022, 37, e111.	2.5	2
4	Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement. <i>The Korean Journal of Hospice and Palliative Care</i> , 2022, 25, 1-11.	0.7	8
5	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1605-1617.	4.2	8
6	Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae. <i>Cancer Research and Treatment</i> , 2021, 53, 983-990.	3.0	8
7	Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 2514.	3.3	17
8	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1755-1769.	4.2	4
9	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 699-711.	2.8	12
10	A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. <i>Haematologica</i> , 2021, 106, 2277-2280.	3.5	9
11	Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study. <i>Cancer Research and Treatment</i> , 2021, 53, 584-592.	3.0	10
12	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR T790M-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1859-1871.	1.1	16
13	Tumor $LAG-3$ and $NY-ESO-1$ expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 619-630.	1.9	8
14	Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 175-181.	1.7	13
15	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. <i>Scientific Reports</i> , 2021, 11, 19712.	3.3	54
16	Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 975-984.	1.7	5
17	Clinical Application of Next-Generation Sequencing-Based Panel to <i>BRAF</i> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 937-944.	4.1	14
18	Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial. <i>Thoracic Cancer</i> , 2020, 11, 62-71.	1.9	27

#	ARTICLE	IF	CITATIONS
19	Severe late dysphagia after multimodal treatment of stage III/IV laryngeal and hypopharyngeal cancer. Japanese Journal of Clinical Oncology, 2020, 50, 185-192.	1.3	15
20	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. Cancer Letters, 2020, 495, 135-144.	7.2	8
21	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: A phase II study. Thoracic Cancer, 2020, 11, 3482-3489.	1.9	16
22	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. Theranostics, 2020, 10, 10838-10848.	10.0	39
23	Efficacy of cyclophosphamide, doxorubicin, and cisplatin for adenoid cystic carcinoma, and their relationship with the pre-chemotherapy tumor growth rate. Chinese Clinical Oncology, 2020, 9, 15-15.	1.2	9
24	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia, 2020, 34, 2184-2197.	7.2	45
25	Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients. Cancer Research and Treatment, 2020, 52, 917-924.	3.0	27
26	GCT-02. THE LONG-TERM OUTCOMES AND SEQUELAE ANALYSIS OF INTRACRANIAL GERMINOMA FROM 187 PATIENTS IN THE SINGLE INSTITUTE: NECESSITY FOR THE ADAPTATION OF RADIOTHERAPY DOSE AND VOLUME. Neuro-Oncology, 2020, 22, 328-329.	1.2	0
27	Anthelmintics as Potential Anti-Cancer Drugs?. Journal of Korean Medical Science, 2020, 35, e75.	2.5	3
28	Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. Annals of Translational Medicine, 2020, 8, 1389.	1.7	0
29	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. Journal of Thoracic Oncology, 2019, 14, 1556-1566.	1.1	28
30	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. Thoracic Cancer, 2019, 10, 2117-2123.	1.9	9
31	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. Lung Cancer, 2019, 136, 122-128.	2.0	38
32	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. Scientific Reports, 2019, 9, 7680.	3.3	36
33	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. Clinical Lung Cancer, 2019, 20, 331-338.e4.	2.6	47
34	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. Cytotherapy, 2019, 21, 603-611.	0.7	15
35	A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncologist, 2019, 24, 751-e231.	3.7	21
36	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. Clinical Lung Cancer, 2019, 20, e442-e451.	2.6	15

#	ARTICLE	IF	CITATIONS
37	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. <i>Oncologist</i> , 2019, 24, e740-e748.	3.7	38
38	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019, 4, e000575.	4.5	5
39	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. <i>BMC Cancer</i> , 2019, 19, 19.	2.6	66
40	Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases. <i>Oral Oncology</i> , 2019, 89, 84-94.	1.5	27
41	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2019, 24, 20.	3.7	29
42	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 885-893.	1.7	9
43	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1313-1323.	1.7	12
44	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1116-1124.	1.7	6
45	The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 169-177.	3.0	3
46	Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 119-127.	3.0	23
47	Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. <i>Cancer Research and Treatment</i> , 2019, 51, 951-962.	3.0	48
48	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1231-1240.	3.0	20
49	Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 894-901.	1.7	0
50	Do Korean Medical Schools Provide Adequate End-of-Life Care Education? A Nationwide Survey of the Republic of Korea's End-of-Life Care Curricula. <i>The Korean Journal of Hospice and Palliative Care</i> , 2019, 22, 207-218.	0.7	4
51	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 736-744.	1.9	31
52	CD21-independent Epstein-Barr virus entry into NK cells. <i>Cellular Immunology</i> , 2018, 327, 21-25.	3.0	12
53	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 459-470.	4.2	132
54	Consensus guidelines for the definition of the end stage of disease and last days of life and criteria for medical judgment. <i>Journal of the Korean Medical Association</i> , 2018, 61, 509.	0.3	19

#	ARTICLE	IF	CITATIONS
55	Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. Cancer Research and Treatment, 2018, 50, 670-680.	3.0	9
56	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2018, 59, 202.	2.2	7
57	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. ESMO Open, 2018, 3, e000332.	4.5	55
58	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study. Blood, 2018, 132, 1617-1617.	1.4	5
59	A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 8575-8575.	1.6	7
60	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE, 2018, 13, e0189766.	2.5	46
61	Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives. Cancer Research and Treatment, 2018, 50, 614-623.	3.0	23
62	The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer. Cancer Research and Treatment, 2018, 50, 720-728.	3.0	14
63	Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. Leukemia and Lymphoma, 2017, 58, 53-63.	1.3	29
64	Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. Leukemia and Lymphoma, 2017, 58, 2624-2632.	1.3	8
65	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. American Journal of Pathology, 2017, 187, 980-986.	3.8	44
66	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nature Communications, 2017, 8, 1050.	12.8	115
67	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 520-528.	1.1	21
68	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. Cancer Research and Treatment, 2017, 49, 1033-1043.	3.0	19
69	The fantasy of a new healthcare policy in Korea. Journal of the Korean Medical Association, 2017, 60, 936.	0.3	1
70	How to build successful hospice-palliative care systems in Korea. Journal of the Korean Medical Association, 2017, 60, 352.	0.3	1
71	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. Journal of Clinical Oncology, 2017, 35, 3065-3074.	1.6	349
72	The Necessity for End-of-Life Care Education: A Preliminary Analysis with Interns at Two University Hospitals. The Korean Journal of Hospice and Palliative Care, 2017, 20, 111-121.	0.7	4

#	ARTICLE	IF	CITATIONS
73	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 97920-97927.	1.8	69
74	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 514-522.	1.7	21
75	Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. <i>Cancer Research and Treatment</i> , 2017, 49, 129-140.	3.0	5
76	The Association between End-of-Life Care and the Time Interval between Provision of a Do-Not-Resuscitate Consent and Death in Cancer Patients in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 502-508.	3.0	26
77	Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 416-422.	3.0	27
78	The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancer Research and Treatment</i> , 2016, 48, 907-916.	3.0	44
79	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 570-578.	1.7	38
80	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. <i>BMC Cancer</i> , 2016, 16, 363.	2.6	37
81	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. <i>Histopathology</i> , 2016, 68, 1079-1089.	2.9	135
82	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2016, 16, 425-433.	1.7	18
83	Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>Clinical Lung Cancer</i> , 2016, 17, 245-252.e1.	2.6	20
84	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 581-590.	2.8	71
85	The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 145-150.	1.5	1
86	Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2016, 7, 161-166.	1.9	16
87	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. <i>Head and Neck</i> , 2016, 38, 277-284.	2.0	14
88	Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 116.	2.6	31
89	Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. <i>Cancer Research and Treatment</i> , 2016, 48, 304-311.	3.0	9
90	Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 215-224.	3.4	128

#	ARTICLE	IF	CITATIONS
91	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 263-270.e2.	2.6	107
92	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). <i>Lung Cancer</i> , 2016, 93, 1-8.	2.0	13
93	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2016, 22, 2261-2270.	7.0	217
94	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. <i>BMC Cancer</i> , 2016, 16, 170.	2.6	30
95	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 873-883.	2.5	17
96	An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. <i>Leukemia and Lymphoma</i> , 2016, 57, 1956-1960.	1.3	15
97	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9013-9013.	1.6	16
98	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 15901-15914.	1.8	125
99	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8389.	3.3	22
100	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 1140-1149.	1.7	26
101	Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 88-97.	3.0	19
102	Poor prognostic factors in human papilloma virus-positive head and neck cancer: Who should not be candidate of de-escalated treatment?. <i>Journal of Clinical Oncology</i> , 2016, 34, 6078-6078.	1.6	0
103	Korean Cancer Patients' Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10067-10067.	1.6	0
104	Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience. <i>Blood</i> , 2016, 128, 4222-4222.	1.4	0
105	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2016, , .	1.7	0
106	Changes in health-related quality of life and quality of care among terminally ill cancer patients and survival prediction: Multicenter prospective cohort study. <i>Palliative and Supportive Care</i> , 2015, 13, 1103-1111.	1.0	10
107	Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-22-dependent proliferation. <i>European Journal of Immunology</i> , 2015, 45, 2335-2342.	2.9	38
108	Personalized cancer medicine: present status and future perspectives. <i>Journal of the Korean Medical Association</i> , 2015, 58, 1021.	0.3	1



#	ARTICLE	IF	CITATIONS
109	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. <i>Cancer Research and Treatment</i> , 2015, 47, 555-563.	3.0	49
110	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0133371.	2.5	7
111	The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 194, 1112-1119.	0.4	19
112	MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2015, 90, 381-387.	2.0	44
113	Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , 2015, 56, 2032-2038.	1.3	43
114	Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2379-2387.	7.0	116
115	Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. <i>Leukemia and Lymphoma</i> , 2015, 56, 1778-1786.	1.3	48
116	Additional Survival Benefit of Involved-Lesion Radiation Therapy After R-CHOP Chemotherapy in Limited Stage Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 91-98.	0.8	22
117	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. <i>Oncologist</i> , 2015, 20, 1119-1120.	3.7	20
118	Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 575-581.	1.8	55
119	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 15035-15049.	1.8	94
120	Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy. <i>Radiation Oncology Journal</i> , 2015, 33, 98.	1.5	22
121	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 891-898.	1.7	10
122	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 182-188.	3.0	3
123	Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 670-675.	3.0	32
124	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with <i>EGFR</i> Mutations. <i>Cancer Research and Treatment</i> , 2015, 47, 630-637.	3.0	21
125	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2015, 47, 607-615.	3.0	93
126	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. <i>Anticancer Research</i> , 2015, 35, 175-82.	1.1	29



#	ARTICLE	IF	CITATIONS
127	Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. <i>Journal of Korean Medical Science</i> , 2014, 29, 1094.	2.5	22
128	Terminal cancer patients'™ and their primary caregivers'™ attitudes toward hospice/palliative care and their effects on actual utilization: A prospective cohort study. <i>Palliative Medicine</i> , 2014, 28, 976-985.	3.1	21
129	Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 940-943.	1.3	9
130	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score. <i>Lung Cancer</i> , 2014, 86, 363-368.	2.0	17
131	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1430.	7.4	136
132	A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group. <i>Oncologist</i> , 2014, 19, 1129-1130.	3.7	16
133	The Understanding of Terminal Cancer and Its Relationship with Attitudes toward End-of-Life Care Issues. <i>Medical Decision Making</i> , 2014, 34, 720-730.	2.4	11
134	Clinical Significance of Downstaging in Patients With Limited-Disease Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, e1-e6.	2.6	1
135	Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1567-1574.	2.5	12
136	The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: A retrospective cohort study. <i>Lung Cancer</i> , 2014, 85, 320-325.	2.0	6
137	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN). <i>Journal of Clinical Oncology</i> , 2014, 32, 7500-7500.	1.6	5
138	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancer Research and Treatment</i> , 2014, 46, 323-330.	3.0	21
139	Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9543-9543.	1.6	0
140	Effect of induction chemotherapy (IC) on survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with chemoradiotherapy: Single center experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17032-e17032.	1.6	0
141	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. <i>Supportive Care in Cancer</i> , 2013, 21, 1437-1444.	2.2	48
142	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. <i>Cancer</i> , 2013, 119, 1195-1202.	4.1	136
143	Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. <i>Supportive Care in Cancer</i> , 2013, 21, 183-190.	2.2	38
144	Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1069-1074.	1.1	110

#	ARTICLE	IF	CITATIONS
145	Life-Sustaining Medical Treatment for Terminal Patients in Korea. <i>Journal of Korean Medical Science</i> , 2013, 28, 1.	2.5	19
146	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. , 2013, 21, 1437.		1
147	A randomized, multicenter, open phase II study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6069-6069.	1.6	4
148	International comparison on the factors influencing reimbursement of expensive cancer drugs.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6614-6614.	1.6	1
149	Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013, 45, 325-333.	3.0	49
150	A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8521-8521.	1.6	0
151	Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2098-2098.	1.6	0
152	The incidence, risk factors and prognostic implications of venous thromboembolism in Asian patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1590-1590.	1.6	0
153	Clinical significance of downstaging in patients treated with chemoradiotherapy for limited-disease small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e18555-e18555.	1.6	0
154	Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Panâ€“Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3337-3344.	1.6	247
155	Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e147-e150.	1.6	47
156	Comparison of Treatment Outcomes Between Involved-field and Elective Nodal Irradiation in Limited-stage Small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 948-954.	1.3	12
157	Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2012, 77, 288-292.	2.0	115
158	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 528-538.	10.7	904
159	Integration of palliative and supportive cancer care in Asia. <i>Lancet Oncology</i> , The, 2012, 13, 445-446.	10.7	27
160	Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. <i>International Journal of Oncology</i> , 2012, 41, 76-82.	3.3	26
161	EGFR mutations as a predictive marker of cytotoxic chemotherapy. <i>Lung Cancer</i> , 2012, 77, 433-437.	2.0	25
162	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. <i>Lung Cancer</i> , 2012, 77, 460-463.	2.0	82

#	ARTICLE	IF	CITATIONS
163	Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. <i>Lung Cancer</i> , 2012, 77, 572-577.	2.0	66
164	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase <sup>+</sup> and matched wild-type advanced nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 3579-3586.	4.1	49
165	Effect of advanced cancer patients' awareness of disease status on treatment decisional conflicts and satisfaction during palliative chemotherapy: a Korean prospective cohort study. <i>Supportive Care in Cancer</i> , 2012, 20, 1309-1316.	2.2	32
166	Influence of chemotherapy on nitric oxide synthase, indoleamine 2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. <i>Cancer Science</i> , 2012, 103, 155-160.	3.9	20
167	The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 1-8.	4.4	28
168	CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. <i>Tumor Biology</i> , 2012, 33, 121-129.	1.8	68
169	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012, 106, 303-313.	2.9	64
170	Health economics of a palliative care unit for terminal cancer patients: a retrospective cohort study. <i>Supportive Care in Cancer</i> , 2012, 20, 29-37.	2.2	18
171	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 395-403.	2.2	28
172	Complementary and Alternative Medicine Use among Cancer Patients at the End of Life: Korean National Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1419-1424.	1.2	21
173	Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7566-7566.	1.6	1
174	Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5552-5552.	1.6	0
175	PPAR $\beta$ ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2011, 406, 389-395.	2.1	32
176	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , 2011, 13, R22.	5.0	187
177	A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. <i>Lung Cancer</i> , 2011, 71, 65-69.	2.0	38
178	Characteristics and issues of guideline to withdrawal of a life-sustaining therapy. <i>Journal of the Korean Medical Association</i> , 2011, 54, 747.	0.3	26
179	Depression, suicide, and Korean society. <i>Journal of the Korean Medical Association</i> , 2011, 54, 358.	0.3	13
180	A possible mechanism of impaired NK cytotoxicity in cancer patients: Down-regulation of DAP10 by TGF- $\beta$ 1. <i>Tumori</i> , 2011, 97, 350-357.	1.1	17

#	ARTICLE	IF	CITATIONS
181	The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines. <i>Anti-Cancer Drugs</i> , 2011, 22, 416-423.	1.4	7
182	Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1474-1480.	1.1	148
183	Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors. <i>Journal of Thoracic Oncology</i> , 2011, 6, 905-912.	1.1	66
184	Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. <i>Cancer Science</i> , 2011, 102, 1972-1976.	3.9	9
185	Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. <i>Journal of Neuro-Oncology</i> , 2011, 103, 595-602.	2.9	29
186	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1301-1308.	2.5	32
187	Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. <i>BMC Cancer</i> , 2011, 11, 435.	2.6	22
188	Clinical dissection of multicentric Castleman disease. <i>Leukemia and Lymphoma</i> , 2011, 52, 1517-1522.	1.3	36
189	VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 143-147.	2.1	4
190	Impact of Awareness of Terminal Illness and Use of Palliative Care or Intensive Care Unit on the Survival of Terminally Ill Patients With Cancer: Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2474-2480.	1.6	71
191	The Effects of the Stromal Cell-Derived Cyclooxygenase-2 Metabolite Prostaglandin E <sub>2</sub> on the Proliferation of Colon Cancer Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 516-523.	2.5	26
192	EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 548-554.	1.3	10
193	Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2965-2971.	1.6	282
194	Attitudes of cancer patients, family caregivers, oncologists and members of the general public toward critical interventions at the end of life of terminally ill patients. <i>Cmaj</i> , 2011, 183, E673-E679.	2.0	67
195	Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center. <i>Hematology</i> , 2011, 16, 73-79.	1.5	7
196	Use of a Decision Aid to Help Caregivers Discuss Terminal Disease Status With a Family Member With Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4811-4819.	1.6	42
197	MicroRNA-146a Downregulates NF- $\kappa$ B Activity via Targeting TRAF6 and Functions as a Tumor Suppressor Having Strong Prognostic Implications in NK/T Cell Lymphoma. <i>Clinical Cancer Research</i> , 2011, 17, 4761-4771.	7.0	168
198	Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 245-252.	1.3	5

#	ARTICLE	IF	CITATIONS
199	Depression and suicide in Korean society. Journal of the Korean Medical Association, 2011, 54, 356.	0.3	4
200	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 320-325.	1.1	54
201	Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line. Oncology Reports, 2010, 23, 1139-43.	2.6	16
202	The life-sustaining treatments among cancer patients at end of life and the caregiver's experience and perspectives. Supportive Care in Cancer, 2010, 18, 189-196.	2.2	31
203	Impact of caregivers' unmet needs for supportive care on quality of terminal cancer care delivered and caregivers' workforce performance. Supportive Care in Cancer, 2010, 18, 699-706.	2.2	65
204	A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC. Tumor Biology, 2010, 31, 659-666.	1.8	4
205	Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer, 2010, 10, 448.	2.6	42
206	Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines. Head and Neck, 2010, 32, 1534-1543.	2.0	21
207	Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma. Cancer Science, 2010, 101, 482-487.	3.9	9
208	First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors. Cancer Science, 2010, 101, 1199-1203.	3.9	48
209	Experiences and Attitudes of Patients With Terminal Cancer and Their Family Caregivers Toward the Disclosure of Terminal Illness. Journal of Clinical Oncology, 2010, 28, 1950-1957.	1.6	134
210	Definitive Radiotherapy With or Without Chemotherapy for T3-4N0 Squamous Cell Carcinoma of the Maxillary Sinus and Nasal Cavity. Japanese Journal of Clinical Oncology, 2010, 40, 542-548.	1.3	25
211	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung Cancer, 2010, 68, 427-432.	2.0	7
212	Justifying the Information on Hospice Care that doctors should provide to Terminally Ill Patients. Korean Journal of Medical Ethics, 2010, 13, 107-122.	0.2	1
213	Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines. International Journal of Molecular Medicine, 2009, 23, 805-10.	4.0	17
214	Patient Autonomy and Advance Directives in Korea. Journal of the Korean Medical Association, 2009, 52, 865.	0.3	49
215	Evidence-based Healthcare in Korea. Journal of the Korean Medical Association, 2009, 52, 934.	0.3	1
216	Preradiation Chemotherapy with ACNU-CDDP in Patients with Newly Diagnosed Glioblastoma: A Retrospective Analysis. Chemotherapy, 2009, 55, 145-154.	1.6	2

#	ARTICLE	IF	CITATIONS
217	Presence of Membrane-Bound TGF- $\beta$ 1 and Its Regulation by IL-2-Activated Immune Cell-Derived IFN- $\gamma$ in Head and Neck Squamous Cell Carcinoma Cell Lines. <i>Journal of Immunology</i> , 2009, 182, 6114-6120.	0.8	14
218	Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. <i>BMC Cancer</i> , 2009, 9, 450.	2.6	22
219	The role of PET/CT in detection of gastric cancer recurrence. <i>BMC Cancer</i> , 2009, 9, 73.	2.6	81
220	Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , 2009, 31, 1121-1128.	2.0	30
221	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 153-160.	2.5	41
222	Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. <i>Annals of Hematology</i> , 2009, 88, 829-838.	1.8	18
223	Extranodal NK/T-cell lymphoma, nasal type: New staging system and treatment strategies. <i>Cancer Science</i> , 2009, 100, 2242-2248.	3.9	68
224	Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. <i>Neuropathology</i> , 2009, 29, 443-449.	1.2	37
225	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , 2009, 65, 80-84.	2.0	118
226	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2009, 65, 204-207.	2.0	29
227	Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 65, 242-246.	2.0	13
228	Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer. <i>Head and Neck</i> , 2008, 30, 346-350.	2.0	8
229	Upfront Chemotherapy and Involved-Field Radiotherapy Results in More Relapses Than Extended Radiotherapy for Intracranial Germinomas: Modification in Radiotherapy Volume Might Be Needed. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 667-671.	0.8	46
230	Treatment Outcomes for Radiotherapy Alone are Comparable With Neoadjuvant Chemotherapy Followed by Radiotherapy in Early-stage Nasopharyngeal Carcinoma. <i>Laryngoscope</i> , 2008, 118, 663-670.	2.0	50
231	Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. <i>BMC Cancer</i> , 2008, 8, 148.	2.6	64
232	Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. <i>BMC Cancer</i> , 2008, 8, 374.	2.6	51
233	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 60, 401-407.	2.0	78
234	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. <i>Lung Cancer</i> , 2008, 61, 30-34.	2.0	89



#	ARTICLE	IF	CITATIONS
235	Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. <i>Lung Cancer</i> , 2008, 62, 381-384.	2.0	20
236	Metastasis-Associated Protein S100A4 and p53 Predict Relapse in Curatively Resected Stage III and IV (M0) Gastric Cancer. <i>Cancer Investigation</i> , 2008, 26, 152-158.	1.3	25
237	Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. <i>Annals of Oncology</i> , 2008, 19, 1477-1484.	1.2	147
238	Association of CD47 with Natural Killer Cell-Mediated Cytotoxicity of Head-and-Neck Squamous Cell Carcinoma Lines. <i>Tumor Biology</i> , 2008, 29, 28-34.	1.8	93
239	Aggressiveness of Cancer-Care near the End-of-Life in Korea. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 381-386.	1.3	94
240	End-of-life Decision in Korea. <i>Journal of the Korean Medical Association</i> , 2008, 51, 524.	0.3	9
241	Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5233-5239.	1.6	175
242	Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment. <i>Acta Oto-Laryngologica</i> , 2007, 127, 121-127.	0.9	4
243	Chemotherapy Use and Associated Factors among Cancer Patients near the End of Life. <i>Oncology</i> , 2007, 72, 164-171.	1.9	60
244	Validation study of the Korean version of the McGill Quality of Life Questionnaire. <i>Palliative Medicine</i> , 2007, 21, 441-447.	3.1	28
245	M20-03: Decision-making of lung cancer patients and family. <i>Journal of Thoracic Oncology</i> , 2007, 2, S211-S212.	1.1	0
246	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 313-319.	1.5	54
247	Palliative chemotherapy for pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2007, 58, 112-115.	2.0	132
248	Nonsurgical Treatment of an Incompletely Excised Primary Adenocarcinoma of Nonpigmented Ciliary Epithelium. <i>Tumori</i> , 2007, 93, 514-517.	1.1	2
249	Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer. <i>Journal of Korean Medical Science</i> , 2007, 22, S115.	2.5	24
250	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. <i>BMC Cancer</i> , 2007, 7, 203.	2.6	126
251	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. <i>BMC Cancer</i> , 2007, 7, 63.	2.6	63
252	Discrepancies in performance status scores as determined by cancer patients and oncologists: are they influenced by depression?. <i>General Hospital Psychiatry</i> , 2007, 29, 555-561.	2.4	20



#	ARTICLE	IF	CITATIONS
253	Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. <i>Supportive Care in Cancer</i> , 2007, 15, 631-636.	2.2	18
254	First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ± radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1274-1282.	1.3	54
255	Epidermal Growth Factor Receptor Mutations and Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 344-350.	1.3	29
256	Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. <i>Lung Cancer</i> , 2006, 52, 75-81.	2.0	11
257	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2006, 54, 201-207.	2.0	35
258	Patient-reported assessment of quality care at end of life: Development and validation of Quality Care Questionnaire—End of Life (QCQ—EOL). <i>European Journal of Cancer</i> , 2006, 42, 2310-2317.	2.8	32
259	Primary Systemic Anaplastic Large Cell Lymphoma in a Single Korean Institution: Clinical Characteristics and Treatment Outcome. <i>Journal of Korean Medical Science</i> , 2006, 21, 633.	2.5	6
260	CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience. <i>Supportive Care in Cancer</i> , 2006, 14, 103-108.	2.2	65
261	EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units. <i>Supportive Care in Cancer</i> , 2006, 14, 329-333.	2.2	41
262	Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters. <i>Cancer Biology and Therapy</i> , 2006, 5, 1502-1510.	3.4	8
263	High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non-Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 4232-4236.	7.0	38
264	Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. <i>Clinical Cancer Research</i> , 2006, 12, 2538-2544.	7.0	245
265	Targeted Therapy of DNA Tumor Virus-Associated Cancers Using Virus-Activated Transcription Factors. <i>Molecular Therapy</i> , 2006, 13, 899-909.	8.2	24
266	Overexpression of Surface-Bound TGF- $\beta$ 1 in Head & Neck Cancer Cell Lines Via Activated Immune Effector Cells-Derived Factors. <i>Journal of Immunotherapy</i> , 2005, 28, 619.	2.4	0
267	Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIe extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , 2005, 106, 3785-3790.	1.4	165
268	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer. <i>International Journal of Cancer</i> , 2005, 113, 109-115.	5.1	152
269	Factors influencing preferences for place of terminal care and of death among cancer patients and their families in Korea. <i>Supportive Care in Cancer</i> , 2005, 13, 565-572.	2.2	68
270	Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer. <i>Journal of Korean Medical Science</i> , 2005, 20, 806.	2.5	17

#	ARTICLE	IF	CITATIONS
271	Docetaxel + 5-Fluorouracil + Cisplatin 3-day Combination Chemotherapy as a First-line Treatment in Patients with Unresectable Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 380-385.	1.3	15
272	Phase II Trial of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 720-726.	1.3	17
273	Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 6-12.	1.3	6
274	Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines. <i>Oncogene</i> , 2005, 24, 6689-6698.	5.9	50
275	Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib. <i>Journal of Clinical Oncology</i> , 2005, 23, 2493-2501.	1.6	736
276	A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus. <i>The Korean Journal of Hematology</i> , 2005, 40, 192.	0.7	0
277	Neoadjuvant Chemotherapy Followed by Radiotherapy in Epidermoid Carcinoma of Anus. <i>Tumori</i> , 2004, 90, 299-302.	1.1	1
278	Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2004, 10, 3708-3716.	7.0	710
279	Tracheal Glomangiosarcoma with Multiple Skin Metastasis. <i>Journal of Dermatology</i> , 2004, 31, 776-778.	1.2	9
280	The Attitudes of Cancer Patients and Their Families Toward the Disclosure of Terminal Illness. <i>Journal of Clinical Oncology</i> , 2004, 22, 307-314.	1.6	163
281	Celecoxib Can Prevent Tumor Growth and Distant Metastasis in Postoperative Setting. <i>Cancer Research</i> , 2004, 64, 3230-3235.	0.9	37
282	Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 400-404.	1.3	23
283	Elevated TGF- $\beta$ 1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients. <i>Journal of Immunology</i> , 2004, 172, 7335-7340.	0.8	481
284	Development of a Cancer Pain Assessment Tool in Korea: A Validation Study of a Korean Version of the Brief Pain Inventory. <i>Oncology</i> , 2004, 66, 439-444.	1.9	124
285	Herpes simplex virus thymidine kinase and granulocyte macrophage colony-stimulating factor combination gene therapy in a murine CT26 cell colon cancer model. <i>Cancer Gene Therapy</i> , 2004, 11, 570-576.	4.6	11
286	Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines. <i>Head and Neck</i> , 2004, 26, 706-715.	2.0	7
287	Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. <i>Cancer</i> , 2004, 100, 1961-1966.	4.1	76
288	Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. <i>Cancer</i> , 2004, 101, 2257-2260.	4.1	70

#	ARTICLE	IF	CITATIONS
289	A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. <i>Cancer</i> , 2004, 101, 2516-2522.	4.1	14
290	Elevated TGF- $\beta$ 1 Secretion and Downmodulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients. <i>Journal of Immunotherapy</i> , 2004, 27, S50.	2.4	4
291	Clinicopathologic features of surgically resected primary gastric lymphoma. <i>World Journal of Gastroenterology</i> , 2004, 10, 1103.	3.3	6
292	Comparative analysis of NK/T-cell lymphoma and peripheral T-cell lymphoma in Korea: Clinicopathological correlations and analysis of EBV strain type and 30-bp deletion variant LMP1. <i>Pathology International</i> , 2003, 53, 735-743.	1.3	31
293	Multicenter Study of Pain and Its Management in Patients with Advanced Cancer in Korea. <i>Journal of Pain and Symptom Management</i> , 2003, 25, 430-437.	1.2	55
294	Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients. <i>Cancer</i> , 2003, 98, 2651-2656.	4.1	58
295	Inhibitory effect of p27KIP1 gene transfer on head and neck squamous cell carcinoma cell lines. <i>Head and Neck</i> , 2003, 25, 44-49.	2.0	16
296	The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. <i>International Journal of Cancer</i> , 2003, 107, 729-738.	5.1	65
297	Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 39, 99-101.	2.0	27
298	Comparison of Intrathecal Chemotherapy for Leptomeningeal Carcinomatosis of a Solid Tumor: Methotrexate Alone Versus Methotrexate in Combination with Cytosine Arabinoside and Hydrocortisone. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 608-612.	1.3	75
299	Therapeutic Outcome of Extranodal NK/T-Cell Lymphoma Initially Treated with Chemotherapy Result of Chemotherapy in NK/T-Cell Lymphoma. <i>Acta Oncologica</i> , 2003, 42, 779-783.	1.8	74
300	Progress and limitations in cancer gene therapy. <i>Genetics in Medicine</i> , 2002, 4, 52S-55S.	2.4	14
301	Docetaxel 75 mg/m <sup>2</sup> is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial. <i>Japanese Journal of Clinical Oncology</i> , 2002, 32, 248-254.	1.3	103
302	A Phase III Randomized Trial of Combined Chemoradiotherapy Versus Radiotherapy Alone in Locally Advanced Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 238-243.	1.3	45
303	Chylothorax in Gorham's Disease. <i>Journal of Korean Medical Science</i> , 2002, 17, 826.	2.5	26
304	Survival of All Cancer Patients in Korea through 2-Year Follow-Up. <i>Journal of Korean Medical Science</i> , 2002, 17, 448.	2.5	2
305	Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 414-419.	0.8	107
306	Hepatitis B Virus Infection and B-Cell Non-Hodgkin's Lymphoma in a Hepatitis B Endemic Area: A Case-control Study. <i>Japanese Journal of Cancer Research</i> , 2002, 93, 471-477.	1.7	102

#	ARTICLE	IF	CITATIONS
307	Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. <i>European Journal of Surgical Oncology</i> , 2001, 27, 464-471.	1.0	35
308	Protest of Korean medical doctors against the government policy in 2000. <i>Journal of Korean Medical Science</i> , 2001, 16, 1.	2.5	4
309	Epstein-Barr virus-associated peripheral T-cell lymphoma in adults with hydroa vacciniforme-like lesions. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 242-247.	1.3	49
310	A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. <i>Cancer</i> , 2001, 91, 1549-1556.	4.1	16
311	Advanced hypopharyngeal carcinoma treatment results according to treatment modalities. <i>Head and Neck</i> , 2001, 23, 713-717.	2.0	41
312	Prognostic Factors of Krukenberg's Tumor. <i>Gynecologic Oncology</i> , 2001, 82, 105-109.	1.4	79
313	Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. <i>Cancer</i> , 2000, 89, 2521-2526.	4.1	34
314	Enhancement of adenoviral transduction with polycationic liposomes in vivo. <i>Cancer Gene Therapy</i> , 2000, 7, 1329-1335.	4.6	14
315	Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 2000, 111, 216-222.	2.5	17
316	A Spindle Cell Tumor of Unknown Origin and Diffuse Bone Marrow Involvement in a Patient with Hypercalcemia. <i>Tumori</i> , 1999, 85, 526-529.	1.1	1
317	Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 901-905.	0.8	21
318	Risk factors for ovarian metastasis following curative resection of gastric adenocarcinoma. , 1999, 85, 1490-1499.		33
319	Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. <i>Cancer</i> , 1999, 86, 1109-1115.	4.1	26
320	Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 1999, 60, 205-214.	4.1	48
321	Synergistic anti-tumor effects with co-expression of GM-CSF and IFN- $\gamma$ in murine tumors. , 1998, 77, 907-912.		12
322	Neoadjuvant chemotherapy and radiotherapy for the treatment of advanced hypopharyngeal carcinoma. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 1998, 19, 40-44.	1.3	15
323	Locoregional Response and Increased Natural Killer Activity after Intratumoral Injection of HLA-B7/1 <sup>22</sup> -Microglobulin Gene in Patients with Cancer. <i>Human Gene Therapy</i> , 1998, 9, 2031-2038.	2.7	12
324	Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis - malonato[(4 R , 5 R )-4,5-bis(aminomethyl)- 2-isopropyl-1,3-dioxolane]platinum(II). <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 41, 109-116.	2.3	6

#	ARTICLE	IF	CITATIONS
325	A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. <i>Cancer</i> , 1993, 71, 3813-3818.	4.1	354